Brought to you by 
Novartis gets option to Adenosine's preclinical program
10 Jul 2007
Executive Summary
Novartis has been granted an option to Adenosine Therapeutics' (developing compounds that target adenosine receptor subtypes) A2B receptor antagonist preclinical program to orally treat Type II diabetes, asthma, and other medical conditions.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Novartis gets option to Adenosine's preclinical program
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice